Literature DB >> 14630815

CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.

Simon Rothenfusser1, Veit Hornung, Maha Ayyoub, Stefanie Britsch, Andreas Towarowski, Anne Krug, Anja Sarris, Norbert Lubenow, Daniel Speiser, Stefan Endres, Gunther Hartmann.   

Abstract

Two distinct types of CpG oligodeoxynucleotide (ODN) have been identified that differ in their capacity to stimulate antigen-presenting cells: CpG-A induces high amounts of interferon-alpha (IFN-alpha) and IFN-beta in plasmacytoid dendritic cells (PDCs), whereas CpG-B induces PDC maturation and is a potent activator of B cells but stimulates only small amounts of IFN-alpha and IFN-beta. Here we examined the ability of these CpG ODNs to enhance peptide-specific CD8+ T-cell responses in human peripheral blood mononuclear cells (PBMCs). The frequency of influenza matrix-specific "memory" CD8+ T cells was increased by both types of CpG ODN, whereas the frequency of Melan-A specific "naive" CD8+ T cells increased on stimulation with CpG-B but not with CpG-A. The presence of PDCs in PBMCs was required for this CpG ODN-mediated effect. The expanded cells were cytotoxic and produced IFN- on peptide restimulation. Soluble factors induced by CpG-A but not CpG-B increased the granzyme-B content and cytotoxicity of established CD8+ T-cell clones, each of which was IFN-alpha/-beta dependent. In conclusion, CpG-B seems to be superior for priming CD8+ T-cell responses, and CpG-A selectively enhances memory CD8+ T-cell responses and induces cytotoxicity. These results demonstrate distinct functional properties of CpG-A and CpG-B with regard to CD8 T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630815     DOI: 10.1182/blood-2003-04-1091

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Transdermal immunization using solid-in-oil nanodispersion with CpG oligodeoxynucleotide adjuvants.

Authors:  Momoko Kitaoka; Ayaka Naritomi; Yuya Hirakawa; Noriho Kamiya; Masahiro Goto
Journal:  Pharm Res       Date:  2014-11-01       Impact factor: 4.200

2.  Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

Authors:  Corinna La Rosa; Jeff Longmate; Simon F Lacey; Teodora Kaltcheva; Rahul Sharan; Denise Marsano; Peter Kwon; Jennifer Drake; Brenda Williams; Sharon Denison; Suenell Broyer; Larry Couture; Ryotaro Nakamura; Sanjeet Dadwal; Morris I Kelsey; Arthur M Krieg; Don J Diamond; John A Zaia
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

Review 3.  Targeting the dendritic cell: the key to immunotherapy in cancer?

Authors:  A Faith; C M Hawrylowicz
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 4.  The role of type I interferon production by dendritic cells in host defense.

Authors:  P Fitzgerald-Bocarsly; D Feng
Journal:  Biochimie       Date:  2007-05-08       Impact factor: 4.079

Review 5.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 6.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history.

Authors:  Patricia Fitzgerald-Bocarsly; Jihong Dai; Sukhwinder Singh
Journal:  Cytokine Growth Factor Rev       Date:  2008-01-11       Impact factor: 7.638

7.  Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.

Authors:  Alexandre de Titta; Marie Ballester; Ziad Julier; Chiara Nembrini; Laura Jeanbart; André J van der Vlies; Melody A Swartz; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

Review 8.  Functional diversity and plasticity of human dendritic cell subsets.

Authors:  Tomoki Ito; Yong-Jun Liu; Norimitsu Kadowaki
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

9.  Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

Authors:  Caroline Aspord; Laetitia Tramcourt; Claire Leloup; Jean-Paul Molens; Marie-Therese Leccia; Julie Charles; Joel Plumas
Journal:  J Invest Dermatol       Date:  2014-04-21       Impact factor: 8.551

10.  Novel APC-like properties of human NK cells directly regulate T cell activation.

Authors:  Jacob Hanna; Tsufit Gonen-Gross; Jonathan Fitchett; Tony Rowe; Mark Daniels; Tal I Arnon; Roi Gazit; Aviva Joseph; Karoline W Schjetne; Alexander Steinle; Angel Porgador; Dror Mevorach; Debra Goldman-Wohl; Simcha Yagel; Michael J LaBarre; Jane H Buckner; Ofer Mandelboim
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.